Phase 2 Trial of MLN9708 in Patients With Relapsed Multiple Myeloma Not Refractory to Bortezomib
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2016
At a glance
- Drugs Ixazomib (Primary) ; Cyclophosphamide; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 04 Oct 2016 Interim results assessing efficacy and toxicity of two different doses of ixazomib 4 mg and 5.5mg given weekly with dexamethosone (n=70), published in the Blood Journal.
- 04 Oct 2016 Interim results (n=70) published in the Blood.
- 12 Sep 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.